Insulin Glargine vs Rosuvastatin: side-by-side comparison
Insulin Glargine (Long-acting insulin analogue) and Rosuvastatin (HMG-CoA reductase inhibitor (statin)) belong to different therapeutic classes and are rarely substitutes for each other. The comparison is useful when a single patient is weighing both options for adjacent or overlapping needs.
| Property | Insulin Glargine | Rosuvastatin |
|---|---|---|
| Therapeutic class | Long-acting insulin analogue | HMG-CoA reductase inhibitor (statin) |
| CAS | 160337-95-1 | 287714-41-4 |
| ATC | A10AE04 | C10AA07 |
| Molecular weight | 6063 Da | 481.54 g/mol |
| Brands with this active ingredient | 1 | 1 |
What they share
Insulin Glargine and Rosuvastatin share the common regulatory framework for prescription active ingredients, bioequivalence standards for generics, and pharmacist oversight. Beyond that, points in common are limited.
Key differences
Insulin Glargine acts by a different mechanism than Rosuvastatin, with indications that barely overlap. Comparing the two is useful when a clinician has mentioned both in the same context or the patient wants to understand why one was prescribed instead of the other.
Mechanisms compared
Insulin Glargine: Insulin glargine binds the insulin receptor with similar affinity to human insulin, activating intracellular signalling that increases glucose uptake in muscle and adipose tissue, suppresses hepatic glucose production an… Rosuvastatin: Rosuvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis.
Indications compared
Insulin Glargine: Insulin glargine is approved as basal insulin therapy in adults and paediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus when oral or non-insulin injectable therapy is insufficien… Rosuvastatin: Rosuvastatin is approved in adults for the treatment of primary hypercholesterolaemia and mixed dyslipidaemia, for the prevention of cardiovascular events in patients at elevated risk and for the secondary prevention of…
Safety profile
Insulin Glargine: Hypoglycaemia is the most important adverse effect of any insulin and can be severe in case of missed meals, prolonged exercise, alcohol intake or interaction with other glucose-lowering agents. Rosuvastatin: Common adverse effects include myalgia, gastrointestinal symptoms, headache and mild elevations of liver enzymes.
Frequently asked questions
Is Insulin Glargine better than Rosuvastatin? ▾
Insulin Glargine and Rosuvastatin are not "better or worse" — they treat different things. The sensible question is which fits your specific need.
Can Insulin Glargine and Rosuvastatin be combined? ▾
Whether they can be combined depends on the indications and the interaction profile of each. If both are in a single prescription, the prescriber has weighed it; in self-medication they should never be combined.
Do they have the same side-effect profile? ▾
No — they belong to different classes and have distinct side-effect profiles. Each has its own prescribing information.
Products with Insulin Glargine
Products with Rosuvastatin
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.